We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Viventia Biotech has received clearance from the FDA to begin a Phase II study evaluating Proxinium for the treatment of patients with chemotherapy-refractory recurrent head and neck cancer.
Axonyx has announced the results of its two curtailed Phase III clinical trials with Phenserine, in development for mild-to-moderate Alzheimer's disease (AD).
MedImmune has submitted a supplemental biologics license application (sBLA) to the FDA for approval to use CAIV-T (cold adapted influenza vaccine, trivalent) in preventing influenza in healthy individuals 5 to 49 years of age.
GlycoGenesys has announced that new findings about the company's cancer drug candidate GCS-100 were recently reported at the XI International Work Shop on Chronic Lymphocytic Leukemia in New York City.
Data from a study of Oscient Pharmaceuticals' fluoroquinolone antibiotic, Factive (gemifloxacin mesylate) tablets, for the potential five-day treatment of mild-to-moderate community-acquired pneumonia (CAP) is being presented at the Second International Conference on Community-Acquired Pneumonia in Montreal, Canada.
Barrier Therapeutics has reported positive Phase IIa data for its oral formulation of Rambazole in the treatment of moderate-to-severe acne and positive biological activity data for its topical formulation of Rambazole.